RAHWAY, N.J., March 2026
Merck Animal Health announced that the U.S. Food and Drug Administration (FDA) has approved BRAVECTO® QUANTUM (fluralaner extended-release injectable suspension), a long-acting parasiticide designed to treat and control Asian longhorned tick and Gulf Coast tick infestations in dogs for up to 12 months. This approval marks a major advancement in veterinary pharmaceutical innovation, offering year-long protection with a single injection, significantly improving compliance and disease prevention in companion animals.
Breakthrough Long-Acting Tick Protection for Dogs
BRAVECTO® QUANTUM introduces a novel extended-release injectable formulation of fluralaner, enabling continuous protection against multiple tick species for 12 months, a duration unmatched by most existing treatments. This innovation addresses a key challenge in veterinary care, where frequent dosing schedules often lead to poor compliance and inconsistent protection.
The drug specifically targets Asian longhorned ticks and Gulf Coast ticks, both of which are associated with serious vector-borne diseases affecting canine health. By providing sustained efficacy, BRAVECTO QUANTUM helps reduce the risk of tick-borne infections, supporting improved long-term health outcomes for dogs.
Importantly, this single-dose injectable therapy eliminates the need for monthly or quarterly treatments, making it a convenient and reliable option for veterinarians and pet owners alike. The extended duration of action also enhances preventive care strategies, particularly in regions with high tick prevalence.
Advertisement
Regulatory Milestone Strengthens Veterinary Pharma Portfolio
The FDA approval represents a significant regulatory milestone, confirming the product’s safety, efficacy, and quality under rigorous evaluation standards. As a veterinary pharmaceutical product, BRAVECTO QUANTUM falls under strict Good Manufacturing Practices (GMP) and clinical evaluation frameworks, ensuring high standards of production and performance.
This approval further strengthens Merck Animal Health’s position as a leader in parasiticide innovation, expanding its BRAVECTO portfolio with a next-generation injectable solution. The development reflects ongoing industry efforts to create long-acting formulations that improve treatment adherence and therapeutic outcomes in veterinary medicine.
In addition, regulatory approval signals readiness for commercial distribution and widespread clinical use, enabling veterinarians to adopt this advanced tick control solution as part of routine preventive care programs.
Addressing Unmet Needs in Companion Animal Health
Tick infestations remain a major concern in companion animal healthcare, contributing to the spread of diseases such as ehrlichiosis, anaplasmosis, and babesiosis. Traditional treatments often require frequent administration, which can lead to missed doses and reduced effectiveness.
BRAVECTO QUANTUM addresses these challenges by delivering consistent, long-term protection, reducing the burden on pet owners while ensuring continuous defense against parasitic threats. Its extended-release formulation also supports improved adherence to preventive care guidelines, a critical factor in managing parasitic diseases effectively.
The product’s ability to provide year-long protection with a single administration represents a significant advancement in veterinary therapeutics, aligning with broader trends toward long-acting, patient-friendly drug delivery systems.
Advancing Innovation in Veterinary Medicine
The approval of BRAVECTO QUANTUM highlights the growing importance of innovation in veterinary pharmaceuticals, particularly in developing solutions that enhance both efficacy and convenience. By combining advanced formulation technology with proven active ingredients, Merck Animal Health continues to drive progress in companion animal care.
This milestone also reflects the role of regulatory science and GxP compliance in bringing high-quality veterinary products to market, ensuring that new therapies meet the highest standards of safety and effectiveness. As the demand for long-acting and preventive treatments continues to rise, innovations like BRAVECTO QUANTUM are expected to play a key role in shaping the future of animal health management.
Source: Merck Animal Health press release
